121 related articles for article (PubMed ID: 35398850)
1. Dynamic Observation: Immune-Privileged Microenvironment Limited the Effectiveness of Immunotherapy in an Intraocular Metastasis Mouse Model.
Tao T; Liu Y; Zhang J; Huang L; Tao Y
Ophthalmic Res; 2022; 65(5):584-594. PubMed ID: 35398850
[TBL] [Abstract][Full Text] [Related]
2. In situ immunogenic clearance induced by a combination of photodynamic therapy and rho-kinase inhibition sensitizes immune checkpoint blockade response to elicit systemic antitumor immunity against intraocular melanoma and its metastasis.
Kim S; Kim SA; Nam GH; Hong Y; Kim GB; Choi Y; Lee S; Cho Y; Kwon M; Jeong C; Kim S; Kim IS
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479026
[TBL] [Abstract][Full Text] [Related]
3. Establishment of humanized tumor microenvironment mouse models based on the injection of peripheral blood mononuclear cells and IFN-γ to evaluate the efficacy of PD-L1/PD-1-targeted immunotherapy.
Lin X; Zeng T; Lin J; Zhang Q; Cheng H; Fang S; Lin S; Chen Y; Xu Y; Lin J
Cancer Biol Ther; 2020; 21(2):130-138. PubMed ID: 31690181
[TBL] [Abstract][Full Text] [Related]
4. PD-L1 expression and T cells infiltration in patients with uncommon EGFR-mutant non-small cell lung cancer and the response to immunotherapy.
Chen K; Cheng G; Zhang F; Zhu G; Xu Y; Yu X; Huang Z; Fan Y
Lung Cancer; 2020 Apr; 142():98-105. PubMed ID: 32120230
[TBL] [Abstract][Full Text] [Related]
5. Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model.
Yu P; Steel JC; Zhang M; Morris JC; Waitz R; Fasso M; Allison JP; Waldmann TA
Proc Natl Acad Sci U S A; 2012 Apr; 109(16):6187-92. PubMed ID: 22474386
[TBL] [Abstract][Full Text] [Related]
6. Albendazole induces an anti-tumor effect and potentiates PD-L1 blockade immunotherapy.
Zhang W; He Z; Liang F; Gong J; Tan L; Yang J; Song S; Xie L; Lu Y
J Cancer Res Clin Oncol; 2023 Dec; 149(18):16763-16778. PubMed ID: 37730912
[TBL] [Abstract][Full Text] [Related]
7. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
[TBL] [Abstract][Full Text] [Related]
8. Increased intraepithelial CD3+ T-lymphocytes and high PD-L1 expression on tumor cells are associated with a favorable prognosis in esophageal squamous cell carcinoma and allow prognostic immunogenic subgrouping.
Jesinghaus M; Steiger K; Slotta-Huspenina J; Drecoll E; Pfarr N; Meyer P; Konukiewitz B; Bettstetter M; Wieczorek K; Ott K; Feith M; Langer R; Weichert W; Specht K; Boxberg M
Oncotarget; 2017 Jul; 8(29):46756-46768. PubMed ID: 28657901
[TBL] [Abstract][Full Text] [Related]
9. Ultra-thin layered double hydroxide-mediated photothermal therapy combine with asynchronous blockade of PD-L1 and NR2F6 inhibit hepatocellular carcinoma.
Lu YF; Zhou JP; Zhou QM; Yang XY; Wang XJ; Yu JN; Zhang JG; Du YZ; Yu RS
J Nanobiotechnology; 2022 Jul; 20(1):351. PubMed ID: 35907841
[TBL] [Abstract][Full Text] [Related]
10. Intratumoral CD73: An immune checkpoint shaping an inhibitory tumor microenvironment and implicating poor prognosis in Chinese melanoma cohorts.
Gao Z; Wang L; Song Z; Ren M; Yang Y; Li J; Shen K; Li Y; Ding Y; Yang Y; Zhou Y; Wei C; Gu J
Front Immunol; 2022; 13():954039. PubMed ID: 36131912
[TBL] [Abstract][Full Text] [Related]
11. The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy.
Qian J; Wang C; Wang B; Yang J; Wang Y; Luo F; Xu J; Zhao C; Liu R; Chu Y
J Neuroinflammation; 2018 Oct; 15(1):290. PubMed ID: 30333036
[TBL] [Abstract][Full Text] [Related]
12. Combined Blockade of IL6 and PD-1/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment.
Tsukamoto H; Fujieda K; Miyashita A; Fukushima S; Ikeda T; Kubo Y; Senju S; Ihn H; Nishimura Y; Oshiumi H
Cancer Res; 2018 Sep; 78(17):5011-5022. PubMed ID: 29967259
[TBL] [Abstract][Full Text] [Related]
13. Exercise sensitizes PD-1/PD-L1 immunotherapy as a hypoxia modulator in the tumor microenvironment of melanoma.
Yan H; Jiang A; Huang Y; Zhang J; Yang W; Zhang W; Liu T
Front Immunol; 2023; 14():1265914. PubMed ID: 37876940
[TBL] [Abstract][Full Text] [Related]
14. Mammary carcinoma cell derived cyclooxygenase 2 suppresses tumor immune surveillance by enhancing intratumoral immune checkpoint activity.
Markosyan N; Chen EP; Evans RA; Ndong V; Vonderheide RH; Smyth EM
Breast Cancer Res; 2013; 15(5):R75. PubMed ID: 24004819
[TBL] [Abstract][Full Text] [Related]
15. PD-L1 expression and CD8+ infiltration shows heterogeneity in juvenile recurrent respiratory papillomatosis.
Liu T; Greenberg M; Wentland C; Sepe B; Bowe S; Diercks G; Huynh T; Mino-Kenudson M; Schlegel R; Kodack D; Benes C; Engelman J; Hartnick C
Int J Pediatr Otorhinolaryngol; 2017 Apr; 95():133-138. PubMed ID: 28576522
[TBL] [Abstract][Full Text] [Related]
16. α-PD-L1 mAb enhances the abscopal effect of hypo-fractionated radiation by attenuating PD-L1 expression and inducing CD8
Wang H; Lin X; Luo Y; Sun S; Tian X; Sun Y; Zhang S; Chen J; Zhang J; Liu X; Liu H; Gong Y; Xie C
Immunotherapy; 2019 Feb; 11(2):101-118. PubMed ID: 30511887
[TBL] [Abstract][Full Text] [Related]
17. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells.
Spranger S; Spaapen RM; Zha Y; Williams J; Meng Y; Ha TT; Gajewski TF
Sci Transl Med; 2013 Aug; 5(200):200ra116. PubMed ID: 23986400
[TBL] [Abstract][Full Text] [Related]
18. Nodular primary cutaneous melanoma is associated with PD-L1 expression.
Giavina-Bianchi M; Giavina-Bianchi P; Sotto MN; Rodig S; Mihm M; Festa Neto C; Duncan LM; Kalil J
Eur J Dermatol; 2020 Aug; 30(4):352-357. PubMed ID: 32969795
[TBL] [Abstract][Full Text] [Related]
19. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
20. IR792-MCN@ZIF-8-PD-L1 siRNA drug delivery system enhances photothermal immunotherapy for triple-negative breast cancer under near-infrared laser irradiation.
Wang Y; Wang H; Song Y; Lv M; Mao Y; Song H; Wang Y; Nie G; Liu X; Cui J; Zou X
J Nanobiotechnology; 2022 Mar; 20(1):96. PubMed ID: 35236356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]